\n<\/p>\n
San Francisco, CA \u2013 Artificial intelligence pioneer Anthropic has officially moved from the purely digital realm into the tangible biological world. On 18 September 2026, the company announced that it has established a physical wet lab in the San Francisco Bay Area to conduct real-world biological experiments and expand its drug AI pipeline.<\/strong><\/p>\n Moving from Simulation to Reality Beyond Visualisation \u2013 Using Lab Robots and Wet Lab Experiments Though the facility will make use of only laboratory automation, it will not be solely software-based; it will directly run physical biology experiments under the close guidance of its AI model Claude.<\/p>\n [ Computational Models (Claude Science) ] [ Model Hardware Standard Protocol Interface ] [ Automated Wet Lab Robotics (Bay Area Facility) ] [ Empirical Biological Feedback ] Away from Computer Simulations, Back to Lab Robots and Biological Validation Rather than solely choosing to simulate experiments in advance, this laboratory will make use of physical automation dictated by Claude.<\/p>\n This will be based on the Model Hardware Standard protocol, which was officially launched in August 2026 and which enables lab robots to execute biological procedures under the direction of a large language model.<\/p>\n [ Computational Models (Claude Science) ] [ Model Hardware Standard Protocol Interface ] [ Automated Wet Lab Robotics (Bay Area Facility) ] [ Empirical Biological Feedback ] Rather than purely automating, the company emphasizes the important role of researchers and human experimenters in its safety architecture.<\/p>\n \u201cWe believe in the power of tight feedback loops, and there\u2019s no substitute for having our own experiences alongside researchers in the trenches trying to develop drugs.\u201d<\/p>\n \u2013 Eric Kaouderer-Abrams, Head of Life Sciences at Anthropic Taking on Neglected Diseases Rather than following the traditional biotech product paradigm, the company\u2019s initial drug discovery operations will focus on preclinical research into neglected and orphan diseases, which have historically been an \u201coff-limits\u201d space for drug companies due to price considerations.<\/p>\n Competitive Positioning and Biosafety Regulations Anthropic\u2019s announcement comes at a time of increased company interest from firms operating in biological AI and at a time when competitors such as Google Deep Mind\u2019s Isomorphic Labs and OpenAI (with its GPT-Rosalind workflow) are moving to leverage models into the physical world.<\/p>\n<\/div>\n By setting up physical wet labs, the company hopes to improve its models using real laboratory data while observing strict Biosafety protocols for autonomous tests.<\/p>\n \u00a0<\/p>\n<\/div>\n